INLYBEST-5 Tablets INLYBEST-5 contains Axitinib, a potent and selective second-generation tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3. By inhibiting ligand-induced receptor autophosphorylation, axitinib blocks downstream signaling pathways, endothelial cell proliferation, and survival, thereby suppressing tumor angiogenesis and growth. It is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.